Yousif Capital Management LLC Lowers Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Yousif Capital Management LLC reduced its stake in Thermo Fisher Scientific Inc. by 1.9%, holding 40,900 shares worth $16.58 million after selling 773 shares in the second quarter.
• Insider trading activity included CEO Marc N. Casper selling 10,000 shares at an average price of $500.96, while CAO Joseph R. Holmes sold 385 shares at $492.63, reflecting significant decreases in their positions.
• JPMorgan Chase & Co. raised its price target for Thermo Fisher Scientific from $600 to $650, while the stock holds a consensus rating of "Moderate Buy" with an average target price of $593.43.

Yousif Capital Management LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 40,900 shares of the medical research company's stock after selling 773 shares during the quarter. Yousif Capital Management LLC's holdings in Thermo Fisher Scientific were worth $16,583,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Nuveen LLC bought a new position in Thermo Fisher Scientific in the 1st quarter valued at $532,360,000. EdgePoint Investment Group Inc. bought a new position in Thermo Fisher Scientific in the 1st quarter valued at $172,139,000. Cohen Investment Advisors LLC grew its stake in Thermo Fisher Scientific by 6,655.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock valued at $167,271,000 after purchasing an additional 331,180 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after purchasing an additional 329,974 shares during the period. Finally, Auto Owners Insurance Co grew its stake in Thermo Fisher Scientific by 6,773.5% in the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company's stock valued at $143,309,000 after purchasing an additional 283,810 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 in the last quarter. 0.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on TMO shares. JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research note on Thursday. Evercore ISI increased their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 7th. Robert W. Baird increased their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday. Finally, William Blair started coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They set an "outperform" rating for the company. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $593.43.

Thermo Fisher Scientific Stock Down 1.8%

Shares of NYSE TMO opened at $524.95 on Monday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The business has a 50-day simple moving average of $488.68 and a two-hundred day simple moving average of $447.49. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market cap of $198.23 billion, a P/E ratio of 30.36, a P/E/G ratio of 2.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the company earned $5.37 EPS. The firm's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.